Watch for Changes With Montelukast and Olopatadine Products

April 2020

A new warning for montelukast (Singulair) and new olopatadine OTCs (Pataday) will bring changes to meds for seasonal allergies.

Singulair (montelukast) has a new boxed warning...since cases of mental health effects (depression, suicidal thoughts, etc) are still being reported despite prior precautions.

FDA now says that montelukast's benefits may NOT outweigh risks...especially for most patients with "hay fever."

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Storage & Disposal Highlight Med Disposal Options for Patients
NSAIDs Look for Voltaren Arthritis Pain Gel on OTC Shelves
Practice Follow Best Practices for Billing Insulin Pens
Cholesterol Nexletol Will Be a New Add-On Med for High Cholesterol
Respiratory & Allergy Watch for Changes With Montelukast and Olopatadine Products
Inventory Management Use Strategies to Minimize Pharmacy Shrink
Med Safety Reduce the Risk of Mishaps Related to Knowledge, Action, or Memory
Antipsychotics Avoid Mix-Ups With the New Antipsychotics Caplyta and Secuado
Migraine Expect Fewer Rxs to Prevent Migraine in Kids

Watch for Changes With Montelukast and Olopatadine Products

Practical advice for a better career, with unlimited access to CE

Table of Contents